Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EEL Transcriptomics
Stockholm, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
EEL Transcriptomics developed a high‑plex spatial transcriptomics assay with single‑cell resolution (EEL FISH/EEL assay) for large tissue samples; the assay and related IP were acquired by Rebus Biosystems for integration into the Rebus Esper spatial omics platform and is being commercialized as a research‑use‑only tool rather than a therapeutic product.[1][2][3][4]
- Industry
- Non-Drug Biotech
02
Partnerships
Rebus Biosystems (acquisition and integration of EEL assay into Rebus Esper spatial omics platform)[1][2][4]
Beyond the preview
Go deeper on EEL Transcriptomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EEL Transcriptomics.